ACTRN12610000866000已完成3 期
A three arm single blind parallel group randomised controlled clinical trial to evaluate the efficacy, acceptability, utilisation and safety of an electronic cigarette (ENDS) as a smoking cessation aid (ASCEND)
Health Research Council NZ0 个研究点目标入组 653 人开始时间: 2010年10月15日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 653
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Participants will be smokers from throughout Auckland
- •who want to stop smoking.
- •2. Are at least 18 years of age,
- •3. Have smoked on average at least 10 cigarettes a day for the past year
- •4. Are able to provide verbal consent
- •5. Have access to a phone
排除标准
- •1. Pregnant women and women who are breastfeeding will be excluded from the trial,
- •2. Current users of another smoking cessation medication ((e.g. other forms of NRT, buproprion [Zyban], clonidine, nortriptyline [Norpress] or vareniciline [Champix])
- •3. Those enrolled in another smoking cessation programme (e.g. Txt2Quit) or trial.
- •4. Had a heart attack, stroke or severe angina in the previous two weeks
- •5. Poorly controlled asthma or other airways disease (from history
- •6. Poorly controlled diabetes mellitus
- •7. Severe allergies
- •8. Poorly controlled psychiatric disorders
- •9. Current chemical dependence other than that involving nicotine.
研究者
相似试验
进行中（未招募）
不适用
A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothiazide 32/12.5 mg and 32/25 mg in Comparison with Candesartan Cilexetil 32 mg Alone in Patients with Inadequate Blood Pressure Control on Monotherapy with Candesartan Cilexetil 32 mgHypertensionEUCTR2005-005718-19-DEAstraZeneca AB4,391
进行中（未招募）
不适用
A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothiazide 32/12.5 mg and 32/25 mg in Comparison with Candesartan Cilexetil 32 mg Alone in Patients with Inadequate Blood Pressure Control on Monotherapy with Candesartan Cilexetil 32 mgHypertensionEUCTR2005-005718-19-SEAstraZeneca AB4,391
进行中（未招募）
1 期
A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothiazide 32/12.5 mg and 32/25 mg in Comparison with Candesartan Cilexetil 32 mg Alone in Patients with Inadequate Blood Pressure Control on Monotherapy with Candesartan Cilexetil 32 mgMedDRA version: 9.0 Level: LLT Classification code 10020772HypertensionEUCTR2005-005718-19-GBAstraZeneca AB2,000
进行中（未招募）
不适用
A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothiazide 32/12.5 mg and 32/25 mg in Comparison with Candesartan Cilexetil 32 mg Alone in Patients with Inadequate Blood Pressure Control on Monotherapy with Candesartan Cilexetil 32 mgMedDRA version: 9.0Level: LLTClassification code 10020772HypertensionEUCTR2005-005718-19-DKAstraZeneca AB2,000
进行中（未招募）
不适用
A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothiazide 32/12.5 mg and 32/25 mg in Comparison with Candesartan Cilexetil 32 mg Alone in Patients with Inadequate Blood Pressure Control on Monotherapy with Candesartan Cilexetil 32 mgMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionHypertensionEUCTR2005-005718-19-LTAstraZeneca AB2,000